Alzheimer's Disease Imaging Biomarkers

Dear Colleagues,

Alzheimer’s disease (AD)—a progressive, neurodegenerative, and incurable disorder—is the most common form of dementia diagnosed in people over the age of 65. AD looms as a major threat to public health in the first half of the 21st Century. Dementia doubles in frequency every five years after age 60, afflicting 1% of those aged 60–64 but rising to 30-40% of those 85 years and older. According to recent national census statistics, by the year 2050, the population of those aged 65 and older in the United States is projected to be 83.7 million, almost double its current estimated number of 43.1 million (in 2012). AD research is progressing steadily, but one aspect continues to elude the basic and clinical sciences: Despite our knowledge of AD pathophysiology and anatomic pathology, in addition to breakthroughs in MRI and PET imaging, a reliable and accurate diagnostic imaging protocol that discriminates AD from other neurodegenerative diseases does not exist. Indeed, neuropathologic examination of postmortem tissue remains the gold standard of AD diagnosis. 

The primary goals of this Special Issue on “Alzheimer's Disease Imaging Biomarkers” are to recount the history of AD imaging breakthroughs, present ongoing cutting edge research, and introduce novel ideas that will advance the field. The Special Issue will include invited and solicited submissions. We welcome your contribution.

With warmest regards,

Prof. Dr. Jonathan J. Wisco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.